Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Financing Activities (2016 - 2025)

vTv Therapeutics' Cash from Financing Activities history spans 12 years, with the latest figure at -$321000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed N/A year-over-year to -$321000.0; the TTM value through Dec 2025 reached $77.4 million, up 47.21%, while the annual FY2025 figure was $77.4 million, 47.21% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$321000.0 at vTv Therapeutics, down from $77.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $77.8 million in Q3 2025 and bottomed at -$321000.0 in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $4.4 million (2022), against an average of $11.5 million.
  • The largest YoY upside for Cash from Financing Activities was 4711.72% in 2023 against a maximum downside of 107.69% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $266000.0 in 2021, then surged by 1278.57% to $3.7 million in 2022, then crashed by 107.69% to -$282000.0 in 2023, then soared by 973.4% to $2.5 million in 2024, then tumbled by 113.03% to -$321000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Cash from Financing Activities are -$321000.0 (Q4 2025), $77.8 million (Q3 2025), and -$42000.0 (Q2 2025).